Financial Performance - The group's operating revenue for Q1 2023 was RMB 10,870,720,838.66, representing a year-on-year increase of 4.68%[3]. - Net profit attributable to shareholders of the listed company reached RMB 986,971,662.49, a significant increase of 116.17% compared to the same period last year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 919,320,722.64, reflecting a growth of 14.78% year-on-year[3]. - The basic earnings per share for the period was RMB 0.37, up 105.56% from the previous year[3][7]. - The company reported a total comprehensive income of RMB 930,767,631.49 for Q1 2023, compared to RMB 365,586,120.33 in Q1 2022, marking an increase of approximately 154.1%[21]. - The net profit for Q1 2023 reached RMB 1,114,254,110.16, compared to RMB 634,163,794.28 in Q1 2022, indicating a significant increase of approximately 75.5%[20]. - The company's non-recurring gains and losses for the period were RMB 68 million, an increase of RMB 412 million compared to the previous year, leading to a net profit increase of 116.17% year-on-year[11]. - The total operating revenue for Q1 2023 was RMB 10,870,720,838.66, an increase from RMB 10,384,857,441.74 in Q1 2022, representing a growth of approximately 4.67%[20]. Assets and Liabilities - The total assets of the group at the end of the reporting period were RMB 107,379,375,391.79, showing a slight increase of 0.20% compared to the end of the previous year[4]. - The total assets as of March 31, 2023, amounted to RMB 48,476,339,825.05, a decrease from RMB 49,535,569,590.56 at the end of 2022[25]. - Total liabilities decreased to RMB 14,007,704,743.99 from RMB 15,300,001,896.39 at the end of 2022, reflecting a reduction of approximately 8.4%[25]. - The company's equity attributable to shareholders rose to RMB 45.39 billion from RMB 44.58 billion, showing a positive trend in retained earnings[19]. - Current assets totaled ¥35.18 billion, down from ¥35.28 billion in the previous quarter, primarily due to a decrease in cash and cash equivalents[18]. - The total amount of accounts receivable increased to ¥7.83 billion from ¥7.59 billion, indicating growth in sales or credit terms[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 326,179[8]. - Shanghai Fosun High Technology (Group) Co., Ltd. holds 885,595,955 shares, accounting for 33.14% of the total shares[8]. - HKSCC Nominees Limited holds 551,358,830 shares, representing 20.63% of the total shares[8]. - The top ten shareholders collectively hold a significant portion of the company's shares, with the largest shareholder holding over 33%[9]. - The report indicates that there are no known related party transactions among the top shareholders[10]. Cash Flow - The group reported a net cash flow from operating activities of RMB 873,244,036.36, reflecting a year-on-year increase of 2.06%[3]. - The cash flow from operating activities was RMB 11,865,511,092.17, compared to RMB 11,339,963,678.13 in Q1 2022, marking an increase of about 4.6%[23]. - The cash inflow from operating activities for Q1 2023 was CNY 371,357,088.18, a recovery from a negative cash flow of CNY 464,722,394.46 in Q1 2022[28]. - The net cash flow from financing activities was RMB 281,971,154.45, down from RMB 1,553,311,047.09 in Q1 2022, indicating a significant decline of approximately 81.8%[24]. - Cash and cash equivalents at the end of Q1 2023 were RMB 12,120,741,361.41, up from RMB 7,351,903,309.40 in Q1 2022, showing an increase of approximately 64.5%[24]. Research and Development - Research and development expenses in Q1 2023 amounted to RMB 968,872,153.04, up from RMB 809,679,912.31 in Q1 2022, reflecting a growth of about 19.6%[20]. - The company launched its first innovative drug, Hanshuan (Sru Li monoclonal antibody injection), for the treatment of extensive-stage small cell lung cancer (ES-SCLC) during the reporting period[12]. - The company’s product, Hanquyou (injection trastuzumab), received acceptance for its BLA application by the FDA, potentially becoming the first domestically produced biosimilar approved in China, the EU, and the US[13]. Strategic Developments - The subsidiary Gland Pharma Limited completed the acquisition of European CDMO company Cenexi, enhancing its strategic layout in the European market[15]. - The company’s subsidiary Sisram plans to acquire the "Photon" brand and channels to strengthen its direct sales in the Chinese medical aesthetics market[15]. - The company received a drug production license for its subsidiary, laying the foundation for the commercialization of its vaccine products[14]. - The company fully repurchased and canceled RMB 1.6 billion of its publicly issued corporate bonds in early 2023[16].
复星医药(02196) - 2023 Q1 - 季度业绩